title: Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
abstract: The family Filoviridae contains three genera, Ebolavirus (EBOV), Marburg virus, and Cuevavirus. Some members of the EBOV genus, including Zaire ebolavirus (ZEBOV), can cause lethal haemorrhagic fever in humans. During 2014 an unprecedented ZEBOV outbreak occurred in West Africa and is still ongoing, resulting in over 10,000 deaths, and causing global concern of uncontrolled disease. To meet this challenge a rapid-acting vaccine is needed. Many vaccine approaches have shown promise in being able to protect nonhuman primates against ZEBOV. In response to the current ZEBOV outbreak several of these vaccines have been fast tracked for human use. However, it is not known whether any of these vaccines can provide protection against the new outbreak Makona strain of ZEBOV. One of these approaches is a first-generation recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing the ZEBOV glycoprotein (GP) (rVSV/ZEBOV). To address safety concerns associated with this vector, we developed two candidate, further-attenuated rVSV/ZEBOV vaccines. Both attenuated vaccines produced an approximately tenfold lower vaccine-associated viraemia compared to the first-generation vaccine and both provided complete, single-dose protection of macaques from lethal challenge with the Makona outbreak strain of ZEBOV.
authors: Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.|Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
authors: Chad E
authors: CE
authors: Mire
authors: Department of Virology and Vaccine Vectors, Profectus BioSciences, Inc., Tarrytown, NY, USA.
authors: Demetrius
authors: D
authors: Matassov
authors: Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.|Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
authors: Joan B
authors: JB
authors: Geisbert
authors: Department of Virology and Vaccine Vectors, Profectus BioSciences, Inc., Tarrytown, NY, USA.
authors: Theresa E
authors: TE
authors: Latham
authors: Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.|Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
authors: Krystle N
authors: KN
authors: Agans
authors: Department of Immunology, Profectus BioSciences, Inc., Tarrytown, NY, USA.
authors: Rong
authors: R
authors: Xu
authors: Department of Immunology, Profectus BioSciences, Inc., Tarrytown, NY, USA.
authors: Ayuko
authors: A
authors: Ota-Setlik
authors: Department of Immunology, Profectus BioSciences, Inc., Tarrytown, NY, USA.
authors: Michael A
authors: MA
authors: Egan
authors: Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.|Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
authors: Karla A
authors: KA
authors: Fenton
authors: Department of Virology and Vaccine Vectors, Profectus BioSciences, Inc., Tarrytown, NY, USA.
authors: David K
authors: DK
authors: Clarke
authors: Department of Virology and Vaccine Vectors, Profectus BioSciences, Inc., Tarrytown, NY, USA.|Department of Immunology, Profectus BioSciences, Inc., Tarrytown, NY, USA.
authors: John H
authors: JH
authors: Eldridge
authors: Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.|Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
authors: Thomas W
authors: TW
authors: Geisbert
mesh_terms: D000354:Africa, Western / Q000453:epidemiology; D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D015023:Democratic Republic of the Congo / Q000453:epidemiology; D046129:Ebola Vaccines / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology*; D029043:Ebolavirus / Q000145:classification / Q000276:immunology*; D005260:Female; D005822:Genetic Vectors / Q000235:genetics; D019142:Hemorrhagic Fever, Ebola / Q000276:immunology / Q000517:prevention & control* / Q000821:virology*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007700:Kinetics; D008252:Macaca fascicularis; D008297:Male; D016019:Survival Analysis; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D018116:Vesiculovirus / Q000235:genetics* / Q000254:growth & development
chemical_list: D000914:Antibodies, Viral; D046129:Ebola Vaccines; D007074:Immunoglobulin G; D014613:Vaccines, Attenuated